Anti-CFD Recombinant Antibody (Lampalizumab) (CAT#: TAB-754)

Recombinant humanized (from mouse) antibody Fab fragment expressed in CHO binding to human CFD. Lampalizumab is a humanized monoclonal antibody designed for the treatment of geographic atrophy secondary to age-related macular degeneration.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Stim

Figure 1 Simulations of free target suppression in vitreous humor expressed as ratio of free target to baseline over time.

Figure 1 Simulations of free target suppression in vitreous humor expressed as ratio of free target to baseline over time.

Solid black line represents the model-predicted vitreous humor free target ratio (FTR) for a typical patient in the CFD4870g study. Shaded region represents the 5th−95th prediction interval. Red, blue, and black lines denote the minimum FTR at 4, 6, and 8 weeks following intravitreal (ITV) lampalizumab administration. Black lines denote trend for a typical patient in CFD4870g study and shaded regions represent 5th−95th prediction intervals.

Le, K. N., Gibiansky, L., van Lookeren Campagne, M., Good, J., Davancaze, T., Loyet, K. M.,... & Jin, J. Y. (2015). Population pharmacokinetics and pharmacodynamics of lampalizumab administered intravitreally to patients with geographic atrophy. CPT: pharmacometrics & systems pharmacology, 4(10), 595-604.

ELISA

Figure 2 Systemic PK.

Figure 2 Systemic PK.

Systemic PK. (A) Simulated serum concentration time course of total lampalizumab (solid red line), free lampalizumab (dashed black line), total CFD (solid blue line), free CFD (solid green line), and the total lampalizumab-CFD complex (dotted magenta line) following ITV administration (1 and 10 mg/eye). (B) The lampalizumab fraction of the total dose that is cleared by linear clearance (red) and TMDD (blue) as a function of the ITV dose. The fractions of the drug eliminated by target-mediated clearance (TMCL) and linear clearance (CL) are defined as total drug elimination through binding to the CFD and through the first-order drug clearance mechanism, respectively, which is normalized by total drug elimination.

Govindan, S. V., Cardillo, T. M., Moon, S. J., Hansen, H. J., & Goldenberg, D. M. (2009). CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clinical Cancer Research, 15(19), 6052-6061.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • Fab - G1 - kappa
  • Species Reactivity
  • Human
  • Applications
  • ELISA, IP, FC, FuncS, Neut, IF, Stim
  • CAS
  • 1278466-20-8
  • Generic Name
  • lampalizumab
  • MW
  • 46.96 kDa
  • Related Disease
  • Age-related macular degeneration (AMD), neovascular (wet)

Product Property

  • Purity
  • >95.0%, determined by analysis by RP-HPLC & analysis by SDS-PAGE.
  • Storage
  • Store it under sterile conditions at -20°C upon receiving. Recommend to pack the protein into smaller quantities for optimal storage.

Applications

  • Application Notes
  • The CFD antibody has been reported in applications of ELISA, IP, FC, FuncS, Neut, IF, Stim.

Target

  • Alternative Names
  • lampalizumab;1278466-20-8;Anti-Factor D;RG7417;166-32;FCFD4514S;CFD;complement factor D (adipsin);D component of complement (adipsin) , DF, PFD, properdin factor D;complement factor D;ADN;properdin factor D;C3 convertase activator;complement factor D prep

Related Resources

  • Biosimilar Overview
Please refer to Lampalizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Lampalizumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "CFD"

Single-domain Antibody

CAT Product Name Application Type
PNBL-034 Recombinant Anti-CHRM2 VHH Single Domain Antibody (9-8) FACS Llama VHH

Rabbit Monoclonal Antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-754. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare